Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high16.750 02/05/17
52 week low5.500 08/12/17
52 week change -5.000 (-31.25%)
4 week volume3,936,556 31/03/18
price11.000
price date1524726094
close11.250

Latest NewsMore

DermaPure manufacturing at CellRight Facility

RNS Number: 8532L Tissue Regenix Group PLC 24 April 2018 Tissue Regenix Group plc Successful completion of technical transfer for DermaPure manufacturing at CellRight Facility First product sales from inhouse manufacturing Leeds, 24 April 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices compan...

Holding(s) in Company

RNS Number: 5146L Tissue Regenix Group PLC 19 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Regeni...

Hardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note

Hardman & Co Hardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note 05-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: CellRight hits the right note CellRight hits the right note - Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has tw...

Annual results for period ended 31 December 2017

RNS Number: 8422I Tissue Regenix Group PLC 26 March 2018 Tissue Regenix Group plc Annual results for period ended 31 December 2017 Group Revenues increase to 5.2m Acquisition of CellRight Technologies completed Significant commercial agreements signed Leeds, 26 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regen...

Publication of Financial Results

RNS Number: 0406I Tissue Regenix Group PLC 16 March 2018 Tissue Regenix Group plc Publication of Financial Results Leeds, 16 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the audit process of its annual financial statements is still ongoing and the audited results for ye...

Hardman & Co: Full-year 2017 - what to look for

RNS Number: 0429H Tissue Regenix Group PLC 08 March 2018 Hardman & Co: Full-year 2017 - what to look for Full-year 2017: what to look for - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus ha...

Long term distribution agreement with Arthrex, Inc

RNS Number: 7649G Tissue Regenix Group PLC 06 March 2018 Tissue Regenix Group plc CellRight Technologies signs multi-year distribution agreement with Arthrex, Inc. Leeds, 06 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces subsidiary CellRight Technologies ("CellR...

Tissue Regenix forges distribution agreement for US urogynaecology market

Regenerative medical devices company Tissue Regenix Group said it had entered into an exclusive distribution partnership...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Latest discussion posts More

  • Re: Recent developments

    Manufacturing of DermaPure established in CellRight facility ....see RNS. Perhaps profitability is nearer than you think TP
    24-Apr-2018
    theprior
  • Re: Recent developments

    Woodford now 26% TP
    20-Apr-2018
    theprior
  • Recent developments

    Two RNSs have been issued recently... Finals on 26/03 and Hardman Research paper 5/04. Both make interesting reading and indicate that the company is making better progress ...
    8-Apr-2018
    theprior

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX